Accueil
Envoyer à un ami
Imprimer
Grand
Petit
Partager
ACTUALITES

Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for ...


- 7 Décembre 2016 modifié le 1 Janvier 1970


  • International survey showed high global EGFR testing rates prior to first-line lung cancer therapy but highlighted a shortfall in the number of test results received before deciding on therapy
  • Nearly one in five patients are at risk of missing out on treatments personalised to their specific lung cancer type
  • In addition, more than half of all physicians surveyed did not recognise differences between available targeted therapies to treat EGFR mutation-positive lung cancer